Abstract
Generally, many drugs including nanomedicine can permeate into a superficial layer of tumors through an enhanced permeability and retention (EPR) effect. However, blood-tumor barrier negatively impacts permeation and accumulation of therapeutic drugs. The active targeting of nanoparticles to tumor endothelial cells (TECs) constitutes a breakthrough for overcoming this stint. Based on integrin αvβ3 (a highly specific TEC biomarker) and CD44 (a biomaker for tumor cells), a synergistic active targeting delivery system is able to target not only tumor blood vessels but also tumor cells. Therefore, a specific ligand of αvβ3, tetraiodothyroacetic acid (tetrac) and a major ligand of CD44, hyaluronan (HA), are employed to decorate on the surface of solid lipid nanoparticles (TeHA-SLNs). As a result, the docetaxel-loaded TeHA-SLNs (TeHA-SLNs/DTX) exhibit an excellent anti-tumor effect in vitro and in vivo through synergistic active-targeting function. This chapter gives an introduction to and discussion of the commonly used production and synthetic methods for tetrac conjugated HA and TeHA-SLNs/DTX. Moreover, the methods for characterization and cell targeting assessment in a αvβ3- and CD44-enriched B16F10 cell line are described. Finally, methods to assess targeting effects and antitumor activity of TeHA-SLNs/DTX in vivo are described.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Hida K, Maishi N, Sakurai Y, Hida Y, Harashima H (2016) Heterogeneity of tumor endothelial cells and drug delivery. Adv Drug Deliv Rev 99:140–147
Song W, Tang Z, Zhang D, Yu H, Chen X (2015) Coadministration of vascular disrupting agents and nanomedicines to eradicate tumors from peripheral and central regions. Small 11:3755–3761
Kratz F, Elsadek B (2012) 8-Clinical impact of serum proteins on drug delivery. J Control Release 161:429–445
Koopaei MN, Dinarvand R, Amini M, Rabbani H, Emami S, Ostad SN et al (2011) 9-Docetaxel immunonanocarriers as targeted delivery systems for HER 2-positive tumor cells: preparation, characterization, and cytotoxicity studies. Int J Nanomedicine 6:1903–1912
Duro-Castano A, Gallon E, Decker C, Vicent MJ (2017) Modulating angiogenesis with integrin-targeted nanomedicines. Adv Drug Deliv Rev, https://doi.org/10.1016/j.addr.2017.05.008
Arosio D, Casagrande C (2016) Advancement in integrin facilitated drug delivery. Adv Drug Deliv Rev 97:111–143
Rothdiener M, Beuttler J, Messerschmidt SK, Kontermann RE (2010) 10-Antibody targeting of nanoparticles to tumor-specific receptors: immunoliposomes. Methods Mol Biol 624:295–308
Jeong JH, Lee M, Kim WJ, Yockman JW, Park TG, Kim YH et al (2005) 11-Anti-GAD antibody targeted non-viral gene delivery to islet beta cells. J Control Release 107:562–570
Zhu L, Chen L, Cao QR, Chen D, Cui J (2011) 12-Preparation and evaluation of mannose receptor mediated macrophage targeting delivery system. J Control Release 152(Suppl 1):e190–e191
Jain A, Agarwal A, Majumder S, Lariya N, Khaya A, Agrawal H et al (2010) 13-Mannosylated solid lipid nanoparticles as vectors for site-specific delivery of an anti-cancer drug. J Control Release 148:359–367
Farokhzad OC, Cheng J, Teply BA, Sherifi I, Jon S, Kantoff PW et al (2006) 14-Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. Proc Natl Acad Sci U S A 103:6315–6320
Xiang D, Zheng C, Zhou SF, Qiao S, Tran PH, Pu C et al (2015) Superior performance of aptamer in tumor penetration over antibody: implication of aptamer-based theranostics in solid tumors. Theranostics 5:1083–1097
Guo S, Lin CM, Xu Z, Miao L, Wang Y, Huang L (2014) 16-Co-delivery of cisplatin and rapamycin for enhanced anticancer therapy through synergistic effects and microenvironment modulation. ACS Nano 8:4996–5009
Brannon-Peppas L, Blanchette JO (2004) 17-Nanoparticle and targeted systems for cancer therapy. Adv Drug Deliv Rev 56:1649–1659
Wang H, Zheng L, Peng C, Shen M, Shi X, Zhang G (2013) 18-Folic acid-modified dendrimer-entrapped gold nanoparticles as nanoprobes for targeted CT imaging of human lung adencarcinoma. Biomaterials 34:470–480
El-Gogary RI, Rubio N, Wang JT, Al-Jamal WT, Bourgognon M, Kafa H et al (2014) 18″-Polyethylene glycol conjugated polymeric nanocapsules for targeted delivery of quercetin to folate-expressing cancer cells in vitro and in vivo. ACS Nano 8:1384–1401
Kirpotin DB, Drummond DC, Shao Y, Shalaby MR, Hong K, Nielsen UB et al (2006) 24-Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. Cancer Res 66:6732–6740
Choi CHJ, Alabi CA, Webster P, Davis ME (2010) 25-Mechanism of active targeting in solid tumors with transferrin-containing gold nanoparticles. Proc Natl Acad Sci U S A 107:1235–1240
Chen W, Jarzyna PA, van Tilborg GAF, Nguyen VA, Cormode DP, Klink A et al (2010) 26-RGD peptide functionalized and reconstituted high-density lipoprotein nanoparticles as a versatile and multimodal tumor targeting molecular imaging probe. FASEB J 24:1689–1699
Huang XH, Peng XH, Wang YQ, Wang YX, Shin DM, El-Sayed MA et al (2010) 27-A reexamination of active and passive tumor targeting by using rod-shaped gold Nanocrystals and covalently conjugated peptide ligands. ACS Nano 4:5887–5896
Gianella A, Jarzyna PA, Mani V, Ramachandran S, Calcagno C, Tang J et al (2011) 28-Multifunctional nanoemulsion platform for imaging guided therapy evaluated in experimental cancer. ACS Nano 5:4422–4433
Chattopadhyay N, Fonge H, Cai ZL, Scollard D, Lechtman E, Done SJ et al (2012) 29-Role of antibody-mediated tumor targeting and route of administration in nanoparticle tumor accumulation in vivo. Mol Pharm 9:2168–2179
Prokopiou EM, Ryder SA, Walsh JJ (2013) 30-Tumour vasculature targeting agents in hybrid/conjugate drugs. Angiogenesis 16:503–524
Salvati A, Pitek AS, Monopoli MP, Prapainop K, Bombelli FB, Hristov DR et al (2013) 31-Transferrin-functionalized nanoparticles lose their targeting capabilities when a biomolecule corona adsorbs on the surface. Nat Nanotechnol 8:137–143
Kunjachan S, Pola R, Gremse F, Theek B, Ehling J, Moeckel D et al (2014) 32-Passive versus active tumor targeting using RGD- and NGR-modified polymeric nanomedicines. Nano Lett 14:972–981
Mousa SA, Bergh JJ, Dier E, Rebbaa A, O’Connor LJ, Yalcin M et al (2008) 33-Tetraiodothyroacetic acid, a small molecule integrin ligand, blocks angiogenesis induced by vascular endothelial growth factor and basic fibroblast growth factor. Angiogenesis 11:183–190
Bergh JJ, Lin HY, Lansing L, Mohamed SN, Davis FB, Mousa S et al (2005) 34-Integrin alpha(v)beta(3) contains a cell surface receptor site for thyroid hormone that is linked to activation of mitogen-activated protein kinase and induction of angiogenesis. Endocrinology 146:2864–2871
Kang CM, Koo HJ, Lee S, Lee KC, Oh YK, Choe YS (2013) 35-Cu-64-labeled tetraiodothyroacetic acid-conjugated liposomes for PET imaging of tumor angiogenesis. Nucl Med Biol 40:1018–1024
Brooks PC, Clark RA, Cheresh DA (1994) b-Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science 264:569–571
Hood JD, Cheresh DA (2002) a-Role of integrins in cell invasion and migration. Nat Rev Cancer 2:91–100
Rebbaa A, Chu F, Davis FB, Davis PJ, Mousa SA (2008) 36-Novel function of the thyroid hormone analog tetraiodothyroacetic acid: a cancer chemosensitizing and anti-cancer agent. Angiogenesis 11:269–276
Qhattal HSS, Hye T, Alali A, Liu XL (2014) 37-Hyaluronan polymer length, grafting density, and surface poly(ethylene glycol) coating influence in vivo circulation and tumor targeting of hyaluronan-grafted liposomes. ACS Nano 8:5423–5440
Huang JB, Zhang H, Yu Y, Chen Y, Wang D, Zhang GQ et al (2014) 38-Biodegradable self-assembled nanoparticles of poly (D,L-lactide-co-glycolide)/hyaluronic acid block copolymers for target delivery of docetaxel to breast cancer. Biomaterials 35:550–566
Shi SJ, Han L, Deng L, Zhang YL, Shen HX, Gong T et al (2014) 41-Dual drugs (microRNA-34a and paclitaxel)-loaded functional solid lipid nanoparticles for synergistic cancer cell suppression. J Control Release 194:228–237
Shi SJ, Han L, Gong T, Zhang ZR, Sun X (2013) 42-Systemic delivery of microRNA-34a for cancer stem cell therapy. Angew Chem Int Ed 52:3901–3905
Wada T, Chirachanchai S, Izawa N, Inaki Y, Takemoto K (1994) 51-Synthesis and properties of hyaluronic acid conjugated nucleic acid analogs-1: synthesis of deacetylhyaluronan and introduction of nucleic acid bases. J Bioact Compat Polym 9:429–447
Crescenzi V, Francescangeli A, Renier D, Bellini D (2002) 52-New cross-linked and sulfated derivatives of partially deacetylated hyaluronan: synthesis and preliminary characterization. Biopolymers 64:86–94
Šimkovic I, Hricovınia M, Šoltés L, Mendichi R, Cosentino C (2000) Preparation of water-soluble/insoluble derivatives of hyaluronic acid by cross-linking with epichlorohydrin in aqueous NaOH/NH4OH solution. Carbohydr Polym 41:9–14
Shi S, Zhou M, Li X, Hu M, Li C, Sheng F, Li Z, Wu G et al (2016) Synergistic active targeting of dually integrin αvβ3/CD44-targeted nanoparticles to B16F10 tumors located at different sites of mouse bodies. J Control Release 235:1–13
Bitter T, Muir HM (1962) A modified uronic acid carbazole reaction. Anal Biochem 4:330–334
Yin H, Zhao F, Zhang DH, Li J (2015) B-Hyaluronic acid conjugated beta-cyclodextrin-oligoethylenimine star polymer for CD44-targeted gene delivery. Int J Pharm 483:169–179
Taherian A, Li XL, Liu YQ, Haas TA (2011) C-Differences in integrin expression and signaling within human breast cancer cells. BMC Cancer 11:293
Miao W, Shim G, Kang CM, Lee S, Choe YS, Choi HG, Oh YK (2013) Cholesteryl hyaluronic acid-coated, reduced graphene oxide nanosheets for anti-cancer drug delivery. Biomaterials 34:9638–9647
Wang YG, Yang TY, Wang X, Dai WB, Wang JC, Zhang XA, Li ZQ, Zhang QA (2011) Materializing sequential killing of tumor vasculature and tumor cells via targeted polymeric micelle system. J Control Release 149:299–306
Shen J, Yin Q, Chen L, Zhang Z, Li Y (2012) Co-delivery of paclitaxel and survivin shRNA by pluronic P85-PEI/TPGS complex nanoparticles to overcome drug resistance in lung cancer. Biomaterials 33:8613–8624
Emanuele S, Lauricella M, Carlisi D, Vassallo B, D’Anneo A, Di Fazio P et al (2007) SAHA induces apoptosis in hepatoma cells and synergistically interacts with the proteasome inhibitor Bortezomib. Apoptosis 12:1327–1338
Acknowledgment
This work is supported by the project of the National Natural Science Foundation of China (81402876) and the Program for “1135” Excellent Talents in Daping Hospital. We also would like to thank Prof. Zhirong Zhang and Xun Sun from Sichuan University for providing B16F10 cell line.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer Science+Business Media New York
About this protocol
Cite this protocol
Shi, S. (2018). Synergistic Active Targeting to B16F10 Tumors by αvβ3/CD44-Targeted Nanoparticles Loaded with Docetaxel. In: Patsenker, E. (eds) Integrin Targeting Systems for Tumor Diagnosis and Therapy. Methods in Pharmacology and Toxicology. Humana Press, New York, NY. https://doi.org/10.1007/7653_2018_4
Download citation
DOI: https://doi.org/10.1007/7653_2018_4
Published:
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-7443-6
Online ISBN: 978-1-4939-7445-0
eBook Packages: Springer Protocols